Skip to Main Content
 

Global Search Box

 
 
 

ETD Abstract Container

Abstract Header

The Commercilazation of a Noval Antithrombotic Drug

Abstract Details

, Master of Sciences, Case Western Reserve University, Biology.
Thrombotic events are the main cause of morbidity and mortality in developed countries, and continue to be an important focus for new therapeutic research. A recent study discovered that thymidine phosphorylase (TYMP) - an enzyme initially purified from human platelets - participates in multiple platelet signaling pathways, and regulates platelet activation and thrombosis. Targeting TYMP might be new antithrombotic therapy solutions. This thesis explores the basic science and pathogenesis of thrombosis, diseases associated with thrombosis, TYMP inhibitor tipiracil and its repositioning use for treatment of thrombotic disorders, and continues with a comprehensive analysis of the business development strategies, including intellectual property, addressable market, competition, regulatory, and reimbursement strategies.
Michael Benard (Committee Chair)
Christopher Cullis (Committee Member)
Leena Chakravarty (Committee Member)
Wei Li (Committee Member)
95 p.

Recommended Citations

Citations

  • Dai, Y. (2017). The Commercilazation of a Noval Antithrombotic Drug [Master's thesis, Case Western Reserve University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=case1505303242046038

    APA Style (7th edition)

  • Dai, Yuheng. The Commercilazation of a Noval Antithrombotic Drug. 2017. Case Western Reserve University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=case1505303242046038.

    MLA Style (8th edition)

  • Dai, Yuheng. "The Commercilazation of a Noval Antithrombotic Drug." Master's thesis, Case Western Reserve University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=case1505303242046038

    Chicago Manual of Style (17th edition)